ACTRN12612000291886招募中未知
Second generation antipsychotic weight gain and the facilitators and barriers to physical activity for adults with serious mental illness: a qualitative study.
Julie Ayliffe0 个研究点目标入组 10 人开始时间: 2012年3月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •People with a diagnosis of serious mental illness by DSMIV or ICD-10 criteria for less than or more than 12 months;
- •Taking second generation antipsychotics;
- •Able to communicate verbally in English.
排除标准
- •Unable to comunicate
研究者
相似试验
已完成
不适用
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and QuetiapineSchizophreniform DisorderMood DisordersSchizophreniaSchizoaffective DisorderNCT00312598University of North Carolina, Chapel Hill30
进行中（未招募）
1 期
Treatment of antipsychotic associated obesity with an antidiabetic agent: the TAO studyObesityEUCTR2012-005404-17-DKCenter for Neuropsychiatric Schizophrenia Research45
已完成
1 期
Study of Amantadine for Weight Stabilization During Olanzapine TreatmentPsychotic DisorderSchizophreniform DisorderMood Disorders With Psychotic FeaturesSchizophreniaSchizoaffective DisorderNCT00287352University of North Carolina, Chapel Hill40
已完成
1 期
Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin ExtractionNormal Non-fluencyNCT02447835Michael Rickels15
Unknown
不适用
Clozapine Induced Weight GainWeight GainAntipsychotic AgentsPharmacogeneticsNCT03996356Cwm Taf University Health Board (NHS)160